Transfer

News

All

Transfer

Public Engagement

Awards & Grants

Diabetes

Stem Cells

Environmental Health

Computational Health

Bioengeineering

Molecular Targets & Therapeutics

Pioneer Campus

Medical worker shows human lungs on blurred background.

Transfer, Environmental Health, LHI,

Helmholtz Munich and Khumbu Start Joint Program on COPD

Helmholtz Munich and Khumbu are collaborating on a new research program led by Prof. Ali Önder Yildirim, Director of the Institute of Lung Health and Immunity at Helmholtz Munich. The collaboration aims to develop a novel therapeutic approach for…

Doctor working with AI Consultans

AI, Transfer, Computational Health, AIH,

Helmholtz Munich Launches M1 Clinical AI Consultants to Bring AI Research to Patient Care

A new interdisciplinary team at Helmholtz Munich aims to bridge one of healthcare AI's longstanding challenges: translating promising algorithms into tools that perform reliably in clinical practice. The M1 Clinical AI Consultants, based at the…

Microscopic view of glioblastoma tumor cells

Transfer, Molecular Targets and Therapeutics, STB,

Helmholtz Munich and Partners Report Phase 1 Results for Targeted Glioblastoma Therapy

Helmholtz Munich, together with the University of Münster and ITM Isotope Technologies Munich SE (ITM), has reported updated preliminary results from a Phase 1 clinical trial evaluating ITM-31, a targeted radiotherapy for glioblastoma. The treatment…

Newborn care

Transfer, Computational Health, ICB, IML,

Helmholtz Munich and Partners Develop AI-Powered Sensor Patch for Neonatal Care

Researchers at Helmholtz Munich, together with international partners, have developed an ultrathin sensor patch capable of non-invasively monitoring key health parameters in preterm infants. The silk-based patch measures temperature, pH, sodium, and…

Helmholtz Munich and Vector Institute Strengthen International AI Research Collaboration

AI, Transfer, Computational Health,

Helmholtz Munich and Vector Institute Strengthen International AI Research Collaboration

Helmholtz Munich and the Vector Institute have signed a Memorandum of Understanding (MOU) to strengthen international collaboration in artificial intelligence (AI) and machine learning. The agreement establishes a formal framework for joint research,…

central cancer cell being attacked by surrounding immune cells (t-cells). Ideal for medical, scientific, oncology, and health-related content

Transfer, Molecular Targets and Therapeutics, VIRO,

Helmholtz Munich Technologies and Champalimaud Foundation TCR Assets Support Cellular Immunotherapy Research

Helmholtz Munich has licensed fusion receptor technologies to the Champalimaud Foundation, where they are being used together with newly acquired T cell receptor assets to support research into engineered T cell therapies.